A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation

Future Journal of Pharmaceutical Sciences

Table 7 Summary of degradation data of DOR, LAM and TDF

Degradation condition	DOR		LAM		TDF
Degradation condition	%Deg	Peak area	%Deg	Peak area	%Deg	Peak area
Acid (0.5 N/60 °C/1 h)	4.05	258,342	4.77	1,190,261	5.19	1,085,169
Base (0.5 N/60 °C/1 h)	3.12	260,826	5.74	1,178,182	4.84	1,089,142
Oxidative (10%w/v H₂O₂/60 °C/1 h)	3.54	259,703	4.91	1,188,582	4.83	1,089,342
Hydrolytic (water/60 °C/1 h)	1.01	266,531	0.87	1,239,093	0.63	1,137,391
Thermal (105 °C/1 day)	1.72	264,614	1.09	1,236,328	1.02	1,132,940
Photolytic (UV radiation at 200-Wh/m²-dark control)	2.49	262,531	1.83	1,227,093	2.03	1,121,391

DOR Doravirine, LAM Lamivudine, TDF Tenofovir disoproxil fumarate, h hours, % percentage, UV ultraviolet, min minute, N normality, °C degree celsius, Wh/m² watt-hour per square metre, % Deg percentage degradation